Brief: 4D Molecular Therapeutics Announces Interim Clinical Data From On-Going Phase 1/2 Clinical Trial Of Intravitreal 4D-150 For Wet Age-Related Macular Degeneration (Wet AMD)

4D Molecular Therapeutics

14/11/2022 17:22

Nov 14 (Reuters) - 4D Molecular Therapeutics Inc
 FDMT.O :
    * 4D MOLECULAR THERAPEUTICS ANNOUNCES INTERIM CLINICAL DATA
FROM
ON-GOING PHASE 1/2 CLINICAL TRIAL OF INTRAVITREAL 4D-150 FOR WET
AGE-RELATED MACULAR DEGENERATION (WET AMD)
    * 4D MOLECULAR THERAPEUTICS INC - FOLLOWING INTRAVITREAL
4D-150,
COHORT 1 PATIENTS' ANNUALIZED ANTI-VEGF INJECTION RATE WAS
REDUCED BY 96.7%
    * 4D MOLECULAR THERAPEUTICS - 80% OF COHORT 1 PATIENTS HAD
NOT
RECEIVE SUPPLEMENTAL AFLIBERCEPT INJECTIONS FOR UP TO ABOUT 10
MONTHS AFTER 4D-150 DOSING
    * 4D MOLECULAR THERAPEUTICS INC - COHORT 1 SAFETY AND
TOLERABILITY
OF 4D-150 DEMONSTRATED TO DATE

Source text for Eikon:  ID:nGNXfLB8n 
Further company coverage:  FDMT.O